1. Home
  2. BLRX vs KPLT Comparison

BLRX vs KPLT Comparison

Compare BLRX & KPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLRX
  • KPLT
  • Stock Information
  • Founded
  • BLRX 2003
  • KPLT 2012
  • Country
  • BLRX Israel
  • KPLT United States
  • Employees
  • BLRX N/A
  • KPLT N/A
  • Industry
  • BLRX Biotechnology: Pharmaceutical Preparations
  • KPLT Diversified Commercial Services
  • Sector
  • BLRX Health Care
  • KPLT Consumer Discretionary
  • Exchange
  • BLRX Nasdaq
  • KPLT Nasdaq
  • Market Cap
  • BLRX 36.0M
  • KPLT 33.2M
  • IPO Year
  • BLRX 2011
  • KPLT N/A
  • Fundamental
  • Price
  • BLRX $0.20
  • KPLT $5.92
  • Analyst Decision
  • BLRX Strong Buy
  • KPLT Hold
  • Analyst Count
  • BLRX 2
  • KPLT 2
  • Target Price
  • BLRX $5.50
  • KPLT $12.00
  • AVG Volume (30 Days)
  • BLRX 1.7M
  • KPLT 24.1K
  • Earning Date
  • BLRX 11-25-2024
  • KPLT 11-06-2024
  • Dividend Yield
  • BLRX N/A
  • KPLT N/A
  • EPS Growth
  • BLRX N/A
  • KPLT N/A
  • EPS
  • BLRX N/A
  • KPLT N/A
  • Revenue
  • BLRX $21,991,000.00
  • KPLT $241,789,000.00
  • Revenue This Year
  • BLRX N/A
  • KPLT $12.92
  • Revenue Next Year
  • BLRX N/A
  • KPLT $6.30
  • P/E Ratio
  • BLRX N/A
  • KPLT N/A
  • Revenue Growth
  • BLRX N/A
  • KPLT 14.99
  • 52 Week Low
  • BLRX $0.19
  • KPLT $5.79
  • 52 Week High
  • BLRX $1.68
  • KPLT $23.54
  • Technical
  • Relative Strength Index (RSI)
  • BLRX 25.94
  • KPLT 36.71
  • Support Level
  • BLRX $0.23
  • KPLT $6.09
  • Resistance Level
  • BLRX $0.56
  • KPLT $6.91
  • Average True Range (ATR)
  • BLRX 0.03
  • KPLT 0.48
  • MACD
  • BLRX 0.00
  • KPLT -0.01
  • Stochastic Oscillator
  • BLRX 11.82
  • KPLT 1.23

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

About KPLT Katapult Holdings Inc.

Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.

Share on Social Networks: